You just read:

Ascend Biopharmaceuticals Announces Encouraging Phase I/IIa Interim Results of ASN-002 Treatment of Nodular Basal Cell Carcinoma (nBCC)

News provided by

Ascend Biopharmaceuticals Ltd

07 Nov, 2016, 09:00 ET